Clinical Trial Update: Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) [Phase 3]

View source ↗

Summary

A Phase 3 extension update reporting efficacy and safety outcomes for patients with primary IgA nephropathy who completed the NEF-301 study and are continuing o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Nefigard

Snippet

Sponsor: Calliditas Therapeutics AB | Conditions: Primary IgA Nephropathy | Phase 3 | Status: COMPLETED | Results posted: 2025-01-03